# Research Proposal: Stakeholder-Adaptive XAI Validation Framework

## 1. Title

**Stakeholder-Adaptive XAI Validation Framework: Enabling Cross-Domain Explainability Comparison Through Meta-Learned Metric Calibration**

## 2. Introduction

### 2.1 Background

The proliferation of artificial intelligence systems across critical domains—healthcare, criminal justice, financial services, and scientific research—has intensified demands for explainable AI (XAI). While numerous XAI methods have emerged (LIME, SHAP, Grad-CAM, counterfactual explanations), a fundamental challenge persists: **the absence of standardized validation approaches across domains**. Current XAI validation is fragmented and domain-specific. Radiologists assess medical imaging explanations through clinical accuracy metrics, auditors evaluate algorithmic fairness explanations via statistical parity tests, and end-users judge comprehensibility through subjective questionnaires. This fragmentation creates three critical problems:

**Problem 1: Incommensurability.** A SHAP explanation achieving 85% clinical accuracy in healthcare cannot be meaningfully compared to a LIME explanation achieving 0.12 statistical parity deviation in fairness auditing. The metrics operate on different scales, measure different constructs, and reflect different stakeholder priorities.

**Problem 2: Knowledge Transfer Barriers.** When XAI researchers demonstrate that counterfactual explanations outperform saliency maps in medical imaging, practitioners in legal AI cannot determine whether this finding transfers to their domain. Each domain reinvents validation protocols, duplicating effort and missing opportunities for systematic knowledge accumulation.

**Problem 3: Method Selection Paralysis.** With over 20 major XAI methods available, practitioners lack evidence-based guidance for selecting approaches that generalize across contexts. Domain-specific validation provides no signal about cross-domain effectiveness.

Recent critical analyses have highlighted these issues. Deck et al. (2023) demonstrated that XAI-fairness validation claims often lack empirical rigor, while Danilevsky et al. (2021) showed that NLP explanation validation remains ad-hoc and inconsistent. Aoki et al. (2024) provided crucial evidence that stakeholder type fundamentally shapes explanation effectiveness—clinicians prioritize different explanation features than data scientists, even when evaluating the same system.

### 2.2 Research Gap

Despite growing recognition of these challenges, **no framework exists for objective cross-domain XAI validation**. Current approaches fall into three categories, each with critical limitations:

1. **Domain-Specific Validation:** High internal validity but zero cross-domain comparability (Khade, 2025; Tjoa & Guan, 2019)
2. **Universal Metrics:** Oversimplified single-score approaches that ignore domain context (e.g., raw fidelity scores)
3. **Qualitative Synthesis:** Narrative reviews lacking quantitative comparability

The field lacks a validation framework that simultaneously:
- Preserves domain-specific validation rigor (within-domain validity ≥0.8)
- Enables objective cross-domain comparison (inter-domain correlation ≥0.7)
- Accounts for stakeholder heterogeneity (clinician vs. auditor vs. end-user)
- Provides actionable guidance for method selection

### 2.3 Research Objectives

This research proposes a **Stakeholder-Adaptive XAI Validation Framework (SAVF)** with three primary objectives:

**Objective 1: Theoretical Foundation.** Establish stakeholder type as a bridging variable enabling cross-domain XAI validation, formalized through a multi-dimensional effectiveness profile model.

**Objective 2: Methodological Innovation.** Develop a meta-learning calibration mechanism that maps heterogeneous domain-specific metrics to unified effectiveness profiles while preserving within-domain validity.

**Objective 3: Empirical Validation.** Demonstrate framework feasibility through a controlled study comparing 20 XAI systems across healthcare and fairness domains with 80 stakeholder evaluators.

### 2.4 Central Hypothesis

**Main Hypothesis (H1):** A meta-learned calibration mechanism can map domain-specific XAI validation metrics (clinical expert evaluation, procedural compliance review, statistical parity tests, user comprehension assessments) to a unified multi-dimensional effectiveness profile across healthcare and fairness domains, achieving >0.7 inter-domain correlation when stakeholder types are matched (clinician-to-clinician, auditor-to-auditor), thereby enabling the first objective cross-domain XAI effectiveness comparison.

**Alternative Hypothesis (H0):** Domain-specific XAI validation metrics are fundamentally incommensurable and cannot be calibrated to produce meaningful cross-domain effectiveness comparisons (inter-domain correlation <0.5).

### 2.5 Significance

This research addresses a critical bottleneck in applied XAI research and practice:

**Scientific Impact:** Establishes the first quantitative framework for cross-domain XAI validation, enabling systematic knowledge accumulation and theory development about what makes explanations effective across contexts.

**Methodological Impact:** Introduces meta-learning to validation metric calibration (novel application domain), creating reusable infrastructure for future XAI evaluation research.

**Practical Impact:** Provides evidence-based guidance for XAI method selection, reducing trial-and-error costs and accelerating deployment in high-stakes domains. A healthcare organization could leverage fairness domain findings to inform medical AI explanation design.

**Policy Impact:** Enables regulatory bodies to develop cross-domain XAI standards grounded in empirical evidence rather than domain-specific intuitions.

## 3. Methodology

### 3.1 Research Design Overview

The research employs a **three-phase mixed-methods design** combining computational modeling, human-subjects experimentation, and quantitative validation:

- **Phase 1:** Metric Library Construction & Stakeholder Taxonomy Development (2-3 months)
- **Phase 2:** Meta-Learning Calibration Model Development (3-4 months)
- **Phase 3:** Empirical Validation Study (2-3 months)

### 3.2 Phase 1: Foundational Infrastructure

#### 3.2.1 Domain-Specific Metric Library

We systematically catalog validation metrics from two pilot domains:

**Healthcare Domain (Medical Imaging):**
- Clinical Accuracy: Radiologist agreement with explanation-highlighted regions (0-100 scale)
- Diagnostic Confidence: Change in diagnostic certainty after viewing explanation (Likert 1-7)
- Time-to-Decision: Reduction in diagnostic time (seconds)
- False Positive Rate: Explanation-induced diagnostic errors (percentage)

**Fairness Domain (Algorithmic Decision Systems):**
- Statistical Parity Deviation: $SPD = |P(\hat{Y}=1|A=0) - P(\hat{Y}=1|A=1)|$ (range: 0-1)
- Equalized Odds Violation: $\max_{y \in \{0,1\}} |P(\hat{Y}=1|A=0,Y=y) - P(\hat{Y}=1|A=1,Y=y)|$
- Procedural Compliance: Auditor assessment of explanation completeness (0-100 scale)
- Stakeholder Trust: User-reported trust in algorithmic decision (Likert 1-7)

Each metric is documented with: operational definition, measurement protocol, typical range, stakeholder relevance, and existing validation evidence.

#### 3.2.2 Stakeholder Taxonomy

We define four stakeholder archetypes based on role, expertise, and evaluation priorities:

1. **Domain Experts (Clinicians/Auditors):** Professional evaluators with domain expertise, prioritize accuracy and compliance
2. **End-Users:** Decision subjects affected by AI systems, prioritize comprehension and fairness
3. **Researchers:** XAI developers and evaluators, prioritize technical fidelity and generalizability
4. **Regulators:** Oversight bodies, prioritize accountability and standardization

For each archetype, we characterize:
- Typical evaluation metrics used
- Explanation feature preferences (from Aoki et al., 2024)
- Decision-making context
- Expertise level requirements

#### 3.2.3 Stakeholder Classification Model

We develop an automated classifier to identify stakeholder type from evaluation behavior:

**Input Features:**
- Evaluation time distribution (fast/slow decisions)
- Metric selection patterns
- Explanation feature attention (eye-tracking or interaction logs)
- Linguistic markers in qualitative feedback

**Architecture:** Random Forest classifier with 50 features

**Training Data:** 200 labeled evaluations from pilot studies (50 per archetype)

**Target Performance:** ≥80% classification accuracy (validated via 5-fold cross-validation)

### 3.3 Phase 2: Meta-Learning Calibration Model

#### 3.3.1 Multi-Dimensional Effectiveness Profile

We define XAI effectiveness as a 4-dimensional vector:

$$\mathbf{E} = [e_{\text{accuracy}}, e_{\text{trust}}, e_{\text{comprehension}}, e_{\text{fairness}}] \in [0,1]^4$$

Where:
- $e_{\text{accuracy}}$: Alignment with ground-truth decision factors
- $e_{\text{trust}}$: Stakeholder confidence in explanation
- $e_{\text{comprehension}}$: Stakeholder understanding of explanation
- $e_{\text{fairness}}$: Perceived equity of explanation process

Each dimension is operationalized through domain-specific measurements but calibrated to a common [0,1] scale.

#### 3.3.2 Calibration Function

The core innovation is a meta-learned calibration function:

$$f_{\theta}: (\mathbf{m}_d, s, d) \rightarrow \mathbf{E}$$

Where:
- $\mathbf{m}_d$: Domain-specific metric vector (e.g., [clinical_accuracy, time_to_decision])
- $s \in \{1,2,3,4\}$: Stakeholder archetype
- $d \in \{\text{healthcare}, \text{fairness}\}$: Domain
- $\theta$: Learned calibration parameters
- $\mathbf{E}$: Calibrated effectiveness profile

**Architecture:** We employ Model-Agnostic Meta-Learning (MAML; Finn et al., 2017) adapted for metric calibration:

$$\theta^* = \arg\min_{\theta} \sum_{d \in \mathcal{D}} \mathcal{L}_d(f_{\theta'_d})$$

Where $\theta'_d = \theta - \alpha \nabla_{\theta} \mathcal{L}_d(f_{\theta})$ represents domain-specific adaptation.

**Loss Function:** We minimize the discrepancy between calibrated profiles and stakeholder consensus rankings:

$$\mathcal{L}_d = \sum_{i,j} \mathbb{1}[\text{rank}(\mathbf{E}_i) \neq \text{rank}_{\text{consensus}}(i)] + \lambda ||\mathbf{E}_i - \mathbf{E}_j||_2 \cdot \mathbb{1}[\text{same\_system}(i,j)]$$

The first term enforces ranking consistency; the second term ensures within-system consistency across stakeholders.

#### 3.3.3 Training Protocol

**Meta-Training Data:**
- 10 XAI systems per domain (20 total)
- 5 evaluations per system per stakeholder archetype (400 total evaluations)
- Domain-specific metrics + stakeholder consensus rankings

**Meta-Learning Procedure:**
1. Sample domain $d$ and stakeholder type $s$
2. Compute domain-specific adaptation: $\theta'_{d,s} = \theta - \alpha \nabla_{\theta} \mathcal{L}_{d,s}(f_{\theta})$
3. Evaluate on held-out systems from same domain: $\mathcal{L}_{d,s}(f_{\theta'_{d,s}})$
4. Update meta-parameters: $\theta \leftarrow \theta - \beta \nabla_{\theta} \sum_{d,s} \mathcal{L}_{d,s}(f_{\theta'_{d,s}})$

**Hyperparameters:**
- Inner learning rate: $\alpha = 0.01$
- Outer learning rate: $\beta = 0.001$
- Regularization: $\lambda = 0.1$
- Training iterations: 10,000

**Validation:** 20% held-out systems for early stopping

### 3.4 Phase 3: Empirical Validation Study

#### 3.4.1 Experimental Design

**Study Type:** Controlled between-subjects experiment with within-subjects XAI system comparison

**Sample:**
- **Participants:** 80 stakeholder evaluators (20 per archetype)
  - 20 clinicians (radiologists with ≥3 years experience)
  - 20 fairness auditors (algorithmic accountability professionals)
  - 20 end-users (individuals affected by medical/fairness AI systems)
  - 20 researchers (XAI/ML researchers with ≥2 publications)

**Recruitment:**
- Clinicians: Partner hospitals and radiology professional associations
- Auditors: Algorithmic justice organizations and consulting firms
- End-users: Community organizations and patient advocacy groups
- Researchers: Academic networks and conference attendees

**Inclusion Criteria:**
- Domain experts: ≥3 years professional experience
- End-users: Direct experience with AI-assisted decisions
- Researchers: ≥2 peer-reviewed publications in XAI/ML
- All: English proficiency, informed consent

#### 3.4.2 XAI Systems Selection

**Healthcare Domain (10 systems):**
- LIME (image segmentation)
- SHAP (feature importance)
- Grad-CAM (saliency maps)
- Integrated Gradients
- Counterfactual explanations (nearest counterfactual image)
- Attention visualization
- Concept activation vectors
- Prototype-based explanations
- Rule extraction (decision tree surrogate)
- Example-based explanations (similar cases)

**Fairness Domain (10 systems):**
- LIME (tabular data)
- SHAP (feature importance)
- Counterfactual explanations (minimal feature changes)
- Anchors (rule-based)
- Contrastive explanations
- Influence functions
- Fairness-aware feature importance
- Causal explanations
- Example-based (similar cases)
- Prototype explanations

**System Complexity Balance:** Each domain includes 3 simple, 4 medium, 3 complex systems (controlled variable)

#### 3.4.3 Evaluation Protocol

**Task Structure:**
Each participant evaluates all 10 systems in their primary domain (healthcare OR fairness):

1. **Standardized Vignette:** Participant receives identical case description (e.g., chest X-ray with pneumonia diagnosis; loan application with rejection decision)

2. **Explanation Presentation:** XAI system provides explanation (randomized order, 5-minute time limit per system)

3. **Domain-Specific Evaluation:** Participant completes domain-native assessment:
   - **Healthcare:** Clinical accuracy rating, diagnostic confidence change, time-to-decision, qualitative feedback
   - **Fairness:** Procedural compliance rating, statistical parity assessment, trust rating, qualitative feedback

4. **Universal Dimensions:** All participants complete:
   - Comprehension test (3 multiple-choice questions about explanation content)
   - Trust scale (7-item Likert scale adapted from Hoffman et al., 2018)
   - Perceived fairness (4-item scale)

**Consensus Ranking:** After individual evaluations, stakeholder groups (20 clinicians, 20 auditors) participate in facilitated consensus sessions to establish gold-standard system rankings within each domain.

#### 3.4.4 Data Collection

**Quantitative Data:**
- Domain-specific metric scores (clinical accuracy, statistical parity, etc.)
- Universal dimension scores (comprehension, trust, fairness)
- Evaluation time logs
- Demographic and expertise covariates

**Qualitative Data:**
- Open-ended feedback on explanation quality
- Consensus session transcripts
- Post-study interviews (subset of 20 participants)

**Total Dataset:**
- 800 system evaluations (80 participants × 10 systems each)
- 40 consensus rankings (2 domains × 20 stakeholder groups)
- 20 in-depth interviews

### 3.5 Analysis Plan

#### 3.5.1 Primary Analysis: Cross-Domain Correlation

**Hypothesis Test:**
- **H1:** Spearman rank correlation between healthcare and fairness system rankings ≥0.7 (after calibration)
- **H0:** Correlation <0.5 (incommensurable domains)

**Procedure:**
1. Apply calibration function to domain-specific metrics: $\mathbf{E}_{\text{healthcare}} = f_{\theta}(\mathbf{m}_{\text{healthcare}}, s, \text{healthcare})$
2. Compute system rankings within each domain based on calibrated profiles
3. Calculate Spearman correlation between healthcare and fairness rankings for matched stakeholder types
4. Statistical test: One-tailed test with $\alpha = 0.05$

**Expected Effect Size:** $\rho = 0.7$ (large effect per Cohen's guidelines)

**Power Analysis:** With 10 systems per domain, power = 0.85 to detect $\rho = 0.7$ at $\alpha = 0.05$

#### 3.5.2 Secondary Analyses

**Analysis 2: Within-Domain Validity**

Test whether calibration preserves domain-specific validity:

$$\rho_{\text{within}} = \text{corr}(\text{rank}_{\text{calibrated}}, \text{rank}_{\text{consensus}}) \geq 0.8$$

**Analysis 3: Stakeholder Classification Accuracy**

Validate automated stakeholder classifier:

$$\text{Accuracy} = \frac{\text{Correct Classifications}}{\text{Total Evaluations}} \geq 0.80$$

Evaluated via confusion matrix and F1-scores per archetype.

**Analysis 4: Multi-Dimensional vs. Single-Score Comparison**

Compare calibrated multi-dimensional profile to naive single-score baselines:

- **Baseline 1:** Raw metric average (unweighted mean of normalized domain metrics)
- **Baseline 2:** PCA first component (dimensionality reduction without meta-learning)
- **Baseline 3:** Domain-agnostic universal metric (e.g., explanation fidelity)

**Metric:** Improvement in cross-domain correlation:

$$\Delta \rho = \rho_{\text{SAVF}} - \rho_{\text{baseline}} \geq 0.15$$

**Analysis 5: Stakeholder Heterogeneity**

Examine whether calibration effectiveness varies by stakeholder type:

$$\rho_{\text{clinician}}, \rho_{\text{auditor}}, \rho_{\text{end-user}}, \rho_{\text{researcher}} \geq 0.7$$

ANOVA to test for significant differences across archetypes.

#### 3.5.3 Qualitative Analysis

**Thematic Analysis:** Code qualitative feedback to identify:
- Explanation features valued across domains
- Domain-specific evaluation priorities
- Calibration failure modes (cases where quantitative calibration contradicts qualitative assessment)

**Consensus Process Analysis:** Analyze consensus session transcripts to understand:
- How stakeholders negotiate evaluation criteria
- Points of disagreement and resolution strategies
- Implicit assumptions about explanation quality

### 3.6 Evaluation Metrics

**Primary Metric:**
- **Cross-Domain Correlation ($\rho_{\text{cross}}$):** Spearman correlation between healthcare and fairness system rankings (target: ≥0.7)

**Secondary Metrics:**
- **Within-Domain Validity ($\rho_{\text{within}}$):** Correlation with consensus rankings (target: ≥0.8)
- **Stakeholder Classification Accuracy:** Percentage correct (target: ≥80%)
- **Multi-Dimensional Improvement ($\Delta \rho$):** Gain over single-score baselines (target: ≥0.15)
- **Inter-Rater Reliability (ICC):** Consistency within stakeholder groups (target: ≥0.7)

**Falsification Criteria:**
- $\rho_{\text{cross}} < 0.5$ → Domains incommensurable (H0 validated)
- $\rho_{\text{within}} < 0.6$ → Calibration degrades validity (framework harmful)
- $\Delta \rho < 0.1$ → Meta-learning adds no value (use simpler baseline)

### 3.7 Ethical Considerations

**IRB Approval:** Full protocol submitted to institutional review board before participant recruitment

**Informed Consent:** All participants provide written consent after reviewing study procedures, risks, and data usage

**Compensation:** Participants receive $100 for 2-hour evaluation session (market rate for professional expertise)

**Data Privacy:** All data de-identified; only aggregate results published; individual evaluations stored on encrypted servers

**Potential Harms:** Minimal risk study; primary concern is participant time burden (mitigated through compensation and flexible scheduling)

## 4. Expected Outcomes & Impact

### 4.1 Expected Outcomes

#### 4.1.1 Quantitative Outcomes

**Primary Outcome:** Cross-domain correlation $\rho_{\text{cross}} = 0.72$ (95% CI: [0.65, 0.79]), demonstrating that meta-learned calibration enables meaningful cross-domain XAI comparison while exceeding the 0.7 target threshold.

**Secondary Outcomes:**
- Within-domain validity maintained: $\rho_{\text{within}} = 0.83$ (healthcare), $0.81$ (fairness)
- Stakeholder classification accuracy: 84% (exceeding 80% target)
- Multi-dimensional improvement: $\Delta \rho = 0.18$ over best baseline
- Inter-rater reliability: ICC = 0.76 (substantial agreement)

**Stakeholder-Specific Findings:**
- Domain experts (clinicians/auditors) show highest cross-domain correlation ($\rho = 0.78$)
- End-users show moderate correlation ($\rho = 0.68$), reflecting greater context-sensitivity
- Researchers show strong correlation ($\rho = 0.74$), validating technical transferability

#### 4.1.2 Qualitative Outcomes

**Transferable Explanation Features:** Thematic analysis identifies 5-7 explanation characteristics valued across domains:
- Contrastive structure ("why this, not that")
- Appropriate granularity (neither too detailed nor too abstract)
- Actionability (clear implications for decisions)
- Uncertainty quantification
- Consistency with domain knowledge

**Domain-Specific Priorities:** Confirms hypothesized differences:
- Healthcare prioritizes clinical accuracy and diagnostic confidence
- Fairness prioritizes procedural transparency and equity metrics
- Both domains value comprehension and trust, but operationalize differently

**Calibration Failure Modes:** Identifies 2-3 systematic cases where quantitative calibration diverges from qualitative consensus, informing framework refinements.

#### 4.1.3 Methodological Outcomes

**Validated Framework Components:**
1. Stakeholder taxonomy with empirical support (80%+ classification accuracy)
2. Multi-dimensional effectiveness profile model
3. Meta-learning calibration architecture
4. Stakeholder consensus validation protocol

**Open-Source Deliverables:**
- SAVF software package (Python library)
- Annotated dataset: 800 XAI system evaluations with stakeholder metadata
- Evaluation protocol templates for new domains
- Pre-trained calibration models for healthcare and fairness domains

### 4.2 Scientific Impact

#### 4.2.1 Theoretical Contributions

**Contribution 1: Stakeholder-Type as Bridging Variable**

Establishes empirical evidence that stakeholder archetypes generalize across domains, enabling like-to-like comparison (clinician-to-clinician, auditor-to-auditor) even when domain contexts differ. This provides theoretical foundation for stakeholder-adaptive validation frameworks.

**Contribution 2: Multi-Dimensional Effectiveness Model**

Challenges single-score XAI evaluation paradigms by demonstrating that multi-dimensional profiles (accuracy, trust, comprehension, fairness) capture effectiveness more completely and enable finer-grained cross-domain comparison.

**Contribution 3: Meta-Learning for Validation**

Extends meta-learning from model parameter optimization to validation metric calibration—a novel application domain with implications for evaluation methodology across machine learning subfields.

#### 4.2.2 Empirical Contributions

**First Cross-Domain XAI Benchmark:** Provides the first quantitative evidence about which XAI methods generalize across domains. Expected finding: Counterfactual explanations and SHAP show strongest cross-domain effectiveness ($\rho > 0.8$), while domain-specific methods (Grad-CAM in healthcare, causal explanations in fairness) show weaker transferability.

**Stakeholder Heterogeneity Evidence:** Quantifies how evaluation priorities differ across stakeholder types, informing adaptive explanation design.

### 4.3 Practical Impact

#### 4.3.1 Method Selection Guidance

**Evidence-Based XAI Selection:** Practitioners gain objective data for choosing XAI methods:
- Healthcare AI developers can leverage fairness domain findings: "Counterfactual explanations achieved 0.78 cross-domain correlation, suggesting strong transferability to medical imaging contexts."
- Fairness auditors can reference healthcare validation: "SHAP explanations maintained 0.81 within-domain validity while enabling cross-domain comparison."

**Cost Reduction:** Organizations avoid expensive trial-and-error by selecting methods with demonstrated cross-domain effectiveness, reducing deployment timelines by estimated 20-30%.

#### 4.3.2 Regulatory Applications

**Standardization Foundation:** Regulatory bodies (FDA for medical AI, FTC for algorithmic fairness) can develop cross-domain XAI standards grounded in empirical evidence rather than domain-specific intuitions.

**Audit Protocols:** Framework provides reusable infrastructure for third-party XAI audits, enabling consistent evaluation across sectors.

#### 4.3.3 Knowledge Transfer Acceleration

**Domain Expansion:** Framework enables rapid validation in new domains (NLP, scientific discovery, legal AI) by:
1. Classifying stakeholder types in new domain
2. Collecting domain-specific metrics
3. Applying pre-trained calibration model with minimal fine-tuning
4. Generating cross-domain effectiveness comparisons

**Expected Generalization:** Preliminary analysis suggests framework will achieve $\rho \geq 0.6$ in new domains without retraining (validated through optional Sub-Hypothesis 4 with NLP domain).

### 4.4 Broader Impact

#### 4.4.1 XAI Research Community

**Methodological Infrastructure:** Open-source SAVF package becomes standard tool for XAI evaluation research, similar to how scikit-learn standardized ML model evaluation.

**Reproducibility:** Standardized protocols reduce evaluation heterogeneity, improving reproducibility of XAI research findings.

**New Research Directions:** Framework enables novel research questions:
- What domain characteristics predict calibration transferability?
- How do stakeholder archetypes evolve with AI literacy?
- Can calibration functions themselves be explained?

#### 4.4.2 Interdisciplinary Collaboration

**Shared Vocabulary:** Multi-dimensional effectiveness profiles provide common language for cross-domain collaboration between healthcare AI researchers, fairness scholars, and HCI experts.

**Comparative Studies:** Enables first rigorous comparative studies of XAI effectiveness across domains, previously impossible due to metric incommensurability.

#### 4.4.3 Societal Impact

**Trust in AI Systems:** By enabling objective XAI validation, framework supports deployment of more trustworthy AI systems in high-stakes domains, potentially improving healthcare outcomes and reducing algorithmic discrimination.

**Stakeholder Empowerment:** End-user archetype inclusion ensures that affected populations' evaluation priorities are systematically incorporated, promoting more equitable AI development.

### 4.5 Limitations and Future Work

#### 4.5.1 Known Limitations

**Scope Limitation:** Pilot study covers only 2 domains (healthcare, fairness); generalization to all 6 workshop domains (NLP, natural science, law, auditing) requires additional validation.

**Stakeholder Sampling:** 20 participants per archetype may not capture full within-archetype heterogeneity (e.g., radiologists vs. pathologists within clinician archetype).

**Temporal Validity:** Stakeholder preferences may evolve as AI literacy increases; calibration models may require periodic retraining.

**Cultural Context:** Study conducted in Western contexts; cross-cultural validation needed for global applicability.

#### 4.5.2 Future Research Directions

**Direction 1: Domain Expansion**

Extend framework to NLP, scientific discovery, and legal AI domains, testing generalization hypothesis and identifying domain characteristics that enable/prevent calibration transferability.

**Direction 2: Dynamic Calibration**

Develop online learning variants that update calibration functions as new evaluation data arrives, addressing temporal validity concerns.

**Direction 3: Explanation Design**

Use calibrated effectiveness profiles to guide XAI method development—optimize explanations directly for multi-dimensional effectiveness rather than single proxy metrics.

**Direction 4: Stakeholder Archetype Refinement**

Investigate finer-grained stakeholder taxonomies (8-12 archetypes) and hierarchical structures (e.g., clinician → radiologist → thoracic radiologist).

**Direction 5: Interpretable Calibration**

Develop interpretable calibration functions that reveal why certain metrics map to effectiveness dimensions, providing mechanistic insights into explanation quality.

### 4.6 Success Criteria

**Minimum Viable Success:**
- Cross-domain correlation $\rho \geq 0.5$ (moderate effect)
- Within-domain validity maintained $\rho \geq 0.7$
- Framework adopted by ≥3 research groups within 12 months

**Target Success:**
- Cross-domain correlation $\rho \geq 0.7$ (strong effect)
- Within-domain validity $\rho \geq 0.8$
- Framework cited in ≥10 publications within 18 months
- Industry pilot deployment in ≥1 organization

**Aspirational Success:**
- Cross-domain correlation $\rho \geq 0.8$ (approaching gold standard)
- Framework becomes standard evaluation tool in XAI community
- Regulatory adoption for XAI auditing standards
- Extension to ≥4 domains with maintained effectiveness

### 4.7 Timeline and Milestones

**Month 1-3 (Phase 1):**
- Milestone 1: Metric library complete (50 metrics documented)
- Milestone 2: Stakeholder taxonomy validated (80% classification accuracy)
- Milestone 3: IRB approval obtained

**Month 4-7 (Phase 2):**
- Milestone 4: Meta-learning model trained (within-domain $\rho \geq 0.8$)
- Milestone 5: Calibration function validated on held-out systems
- Milestone 6: Participant recruitment complete (80 stakeholders enrolled)

**Month 8-10 (Phase 3):**
- Milestone 7: Data collection complete (800 evaluations)
- Milestone 8: Primary analysis complete (cross-domain $\rho$ calculated)
- Milestone 9: Qualitative analysis complete (thematic coding)
- Milestone 10: Manuscript submitted to top-tier venue (NeurIPS, ICML, FAccT)

**Month 11-12 (Dissemination):**
- Milestone 11: Open-source package released
- Milestone 12: Workshop presentation at XAI conference
- Milestone 13: Industry engagement (pilot deployment discussions)

---

**Total Duration:** 10-12 months  
**Budget Estimate:** $150,000 (participant compensation, computational resources, personnel)  
**Personnel:** 1 PI, 2 PhD students, 1 research coordinator  
**Computational Resources:** Moderate (GPU cluster for meta-learning training)

This research represents a critical step toward systematic, evidence-based XAI evaluation, addressing a fundamental challenge identified by the workshop: enabling knowledge transfer and objective comparison across the diverse applications of explainable AI.